In contrast to tau-PET agents, 18F-FDG-PET is one of the most widely available and utilized nuclear imaging modalities in current clinical practice.92,93 FDG-PET has the support of multiple professional societies in the diagnosis of dementia and is accessible at many medical centres.94-100 We hope that our proposed model could help maximize the clinical utility of the FDG-PET. The gene discussed is MAPT; the disease is dementia.